Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Prostate Adenocarcinoma

Prostate Adenocarcinoma

17

Pipeline Programs↗

34

Active Trials↗

11

Companies Involved↗

Prostate Adenocarcinoma is an emerging landscape with 17 programs across 11 companies. 7 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

30/100

Mech. Concentration

60/100

Completion Rate

71/100

Attrition Rate

6/100

Pipeline

Programs by Phase

Preclinical1

Local Chemotherapy

University Hospital, Rouen

Phase 11

Fludarabine

Sanofi

Phase 28

Nilutamide

Advanz Pharma

Fluciclovine F18

Emory University

Androgen Receptor Pathway Inhibitor

University of Washington

Transdermal Estrogen

University of Washington

Eligard

HanAll BioPharma Co., Ltd.

Phase 37

Abiraterone

Johnson & Johnson

Buserelin

NCIC Clinical Trials Group

Histrelin

University of New Hampshire

Goserelin

TerSera Therapeutics LLC

Leuprolide Acetate

Eastern Cooperative Oncology Group

Approved

No programs

Analysis

Modality Breakdown

93%

Small molecule

14 of 15 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 88% of 17 pipeline programs.

Analysis

Trial Status

50

clinical trials

Recruiting18 · 36%

Active, not recruiting14 · 28%

Completed10 · 20%

Unknown status2 · 4%

Terminated2 · 4%

Not yet recruiting2 · 4%

Other2 · 4%

Clinical Trials

Trial Activity

50 trials

Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide Combined With Metastasis-Directed Stereotactic Body Radiotherapy for Oligorecurrent Prostate Adenocarcinoma (ANDROMEDA)

Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT07150715·107 enrolled

Two-fraction High Dose Rate Brachytherapy as Monotherapy Delivered Three Hours Apart in Localized Prostate Cancer: A Pilot Study

Recruiting·UUniversity of California, San Francisco·Preclinical·NCT05665738·17 enrolled

The Phase III 'High Five Trial' Five Fraction Radiation For High-Risk Prostate Cancer

Recruiting·NRG Oncology·Phase 3·NCT05946213·1,209 enrolled

Phase II Randomized Trial of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC).

Recruiting·OOntario Clinical Oncology Group (OCOG)·Phase 2·NCT06654336·162 enrolled

Dynamic Assessments of Molecular Response to Guide Early 177Lu-PSMA-617 Treatment Discontinuation: The DYNAMO Study

Recruiting·UUniversity of Washington·Phase 2·NCT07698535·64 enrolled

A Phase 2 Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06022822·90 enrolled

Phase 2 Study of High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for Intermediate and High Risk Localized Prostate Adenocarcinoma (HYDRA)

Recruiting·JJonsson Comprehensive Cancer Center·Preclinical·NCT04945642·52 enrolled

A Phase 1 Study to Establish the Feasibility of Enolen (tm) for the Local Delivery of Enzalutamide in Patients With Prostate Cancer

Recruiting·AAlessa Therapeutics Inc.·Phase 1·NCT06257693·45 enrolled

Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes

Recruiting·—·Phase 2·NCT05832086·138 enrolled

Prospective Single-Center Randomized Study Of Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound (HIFU)

Recruiting·CCase Comprehensive Cancer Center·Preclinical·NCT05610852·276 enrolled

Strategic ENdocrine and Targeted Radiation therapY

Recruiting·UUniversity of California, San Diego·Phase 2·NCT07364071·150 enrolled

ART of SABR: A Randomized Phase II Trial of Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer: Two Versus Five Fractions

Recruiting·MMayo Clinic·Preclinical·NCT06325046·164 enrolled

Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RARP in the Treatment Of Prostate Cancer (SINO-TOP)

Recruiting·SShanghai Changzheng Hospital·Preclinical·NCT06238713·480 enrolled

High Precision Stereotactic Radiotherapy to the Whole Prostate With Focal Boost and Varying Hormonal Therapy (HEATWAVE)

Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT06067269·95 enrolled

Prostate Specific Membrane Antigen (PSMA) or Fluciclovine (FACBC) PET/CT Site-Directed Therapy of OLigometASTatic Prostate Cancer (P-Flu-BLAST-PC): A Multicenter Study

Recruiting·UUniversity of Washington·Phase 2·NCT04175431·100 enrolled

Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)